Scientific Research
Therapeutic effect of tofetib combined with methotrexate in treatment of rheumatoid arthritis
Li Huiying, Jiang Guoping, Lyu Yingchun
Published 2023-05-15
Cite as IMHGN, 2023, 29(10): 1413-1416. DOI: 10.3760/cma.j.issn.1007-1245.2023.10.018
Abstract
ObjectiveTo explore the therapeutic effects of tofetib combined with methotrexate, recombinant human tumor necrosis factor receptor Ⅱ IgG Fc fusion protein for injection combined with methotrexate, and methotrexate in the treatment of rheumatoid arthritis (RA).
MethodsNinety RA patients treated in Jilin Provincial People's Hospital from January 2020 to January 2022 were divided into groups A, B, and C by the random number table method, with 30 cases in each group. In group A, there were 18 males and 12 females; they were (60.06±4.27)years old. In group B, there were 16 males and 14 females; they were (60.25±4.33) years old. In group C, there were 18 males and 12 females; they were (59.43±4.06) years old. Group A were treated with methotrexat, group B with tropinib and methotrexate, and group C with recombinant human tumor necrosis factor receptor Ⅱ IgG Fc fusion protein and methotrexate, for 24 consecutive weeks. The clinical efficacies, clinical symptoms and laboratory indicators before and after the treatment, and adverse reactions of the three groups were compared. χ2, t, and F tests were applied.
ResultsThe total effective rate of group B was 93.33% (28/30), higher than those of groups C [83.33% (25/30)] and A [66.67% (20/30)], with a statistical difference (P<0.05). The morning stiffness times, joint tenderness numbers, and joint swelling numbers 8 and 24 weeks after the treatment in group B were lower than those before the treatment, and were lower than those in groups C and A (all P<0.05). The levels of erythrocyte sedimentation rate (ESR), rheumatoid factors (RF), and C-reactive protein (CRP) 8 and 24 weeks after the treatment in group B were lower than those in groups C and A (all P<0.05). The incidence of adverse reactions in group B was 6.67% (2/30), which was lower than those in groups C [13.33% (4/30)] and A [20.00% (6/30)], with no statistical difference among the three groups (P>0.05).
ConclusionsTofatib combined with methotrexate in the treatment of patients with RA can effectively improve their clinical symptoms and inhibit the indicators of disease activity. The clinical efficacy is better than that of methotrexate alone and recombinant human tumor necrosis factor receptor Ⅱ IgG Fc fusion protein combined with methotrexate, and the safety is good.
Key words:
Rheumatoid arthritis; Tofatib; Methotrexate; Efficacy; Security
Contributor Information
Li Huiying
Department of Rheumatology and Immunology, Jilin Provincial People's Hospital, Changchun 130021, China
Jiang Guoping
Department of Rheumatology and Immunology, Jilin Provincial People's Hospital, Changchun 130021, China
Lyu Yingchun
Department of Rheumatology and Immunology, Jilin Provincial People's Hospital, Changchun 130021, China
